Literature DB >> 25897373

Immunological parameters as a new lead in the diagnosis of ovarian cancer.

T Baert1, D Timmerman2, I Vergote1, A Coosemans1.   

Abstract

Ovarian cancer is the leading cause of pelvic gynecological cancer death in Europe. Prognosis is poor in women diagnosed at stage III to IV or in case disease recurs. Platin-based chemotherapy and radical surgery have already improved prognosis significantly. Novel strategies in the treatment of ovarian cancer are being searched for. The study of the immune system as a valuable parameter in the development of ovarian cancer has been neglected for a long time. Nevertheless, this is a field in full progression and might open new perspectives in the diagnosis and prognosis of ovarian cancer patients and could lead to a more motivated choice of targeted therapies.

Entities:  

Keywords:  Ovarian cancer; diagnosis; immunosuppression; myeloid derived suppressor cells; prognostic marker; regulatory T cell; tumor-associated macrophages

Year:  2015        PMID： 25897373      PMCID： PMC4402445     

Source DB:  PubMed          Journal:  Facts Views Vis Obgyn        ISSN： 2032-0418


  31 in total

1.  Imaging techniques for the pre-surgical diagnosis of adnexal tumours.

Authors:  Jeroen Kaijser; Vincent Vandecaveye; Christophe M Deroose; Andrea Rockall; Isabelle Thomassin-Naggara; Tom Bourne; Dirk Timmerman
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2014-04-13       Impact factor: 5.237

2.  Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer.

Authors:  Faruk Tas; Senem Karabulut; Murat Serilmez; Rumeysa Ciftci; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2013-12-06

Review 3.  Myeloid-derived suppressor cells in human cancer.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

4.  Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study.

Authors:  Alexander Mustea; Elena-Ioana Braicu; Dominique Koensgen; Shuhui Yuan; P M Sun; Florin Stamatian; Werner Lichtenegger; Frank Chih-Kang Chen; Radoslav Chekerov; Jalid Sehouli
Journal:  Cytokine       Date:  2008-12-13       Impact factor: 3.861

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 6.  History of myeloid-derived suppressor cells.

Authors:  James E Talmadge; Dmitry I Gabrilovich
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

7.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 9.  Tumor-associated macrophages: from mechanisms to therapy.

Authors:  Roy Noy; Jeffrey W Pollard
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

10.  Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.

Authors:  Bozena Dobrzycka; Beata Mackowiak-Matejczyk; Katarzyna Maria Terlikowska; Bozena Kulesza-Bronczyk; Maciej Kinalski; Slawomir Jerzy Terlikowski
Journal:  Tumour Biol       Date:  2015-01-12
View more
  2 in total

1.  Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

Authors:  An Coosemans; Judit Decoene; Thaïs Baert; Annouschka Laenen; Ahmad Kasran; Tina Verschuere; Sven Seys; Ignace Vergote
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

2.  A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?

Authors:  A Coosemans; T Baert; I Vergote
Journal:  Facts Views Vis Obgyn       Date:  2015
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.